Guabello Gregorio
Research Subjects
Research Interests
Guabello Gregorio has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Rossi
IRCCS Ospedale Galeazzi-Sant’Ambrogio, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
2 shared publications - Bertini Jacopo
Division of Internal Medicine, Endocrinology and Metabolic Diseases, I.R.C.C.S. Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy
2 shared publications - Giovanni Grandi
Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena
2 shared publications - Marco Bonomi
Department of Endocrine and Metabolic Diseases, I.R.C.C.S. Istituto Auxologico Italiano, Milan, Italy
2 shared publications - Ruotolo Elena
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
2 shared publications - Sabrina Corbetta
Bone Metabolism Diseases and Diabetes Unit, IRCCS Istituto Auxologico Italiano, Via L. Ariosto 9, 20145, Milan, Italy.
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (8) , 2091
Correction: Impact of estroprogestin therapies on bone health from adolescence to postmenopause
- 28 April 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (8) , 2091
Open AccessCorrection: Impact of estroprogestin therapies on bone health from adolescence to postmenopause
- Open Access
- 18 February 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (10) , 1-16
Impact of estroprogestin therapies on bone health from adolescence to postmenopause
Background: Estrogens are fundamental to bone health, exerting life-long effects onbone metabolism. They regulate skeletal growth and maturation during adolescence andmaintain bone remodeling in adulthood. The decline in estrogen levels during perimenopauseand postmenopause leads to bone mass loss. Emerging evidence also supports a role forprogestins in bone metabolism. Several estrogen-progestins formulations are available andwidely used for contraception in fertile women and as hormone replacement therapy (HRT) incases of primary or secondary ovarian insufficiency as well as in physiologic menopause.Advances in both synthetic and natural preparations allowed for more personalized treatmentapproaches. When selecting estrogen-progestin therapies, it is essential to consider their impacton bone health and remodelling. Objective: This narrative review examines the effects of variousestrogen-progestin regimens on bone metabolism across the female lifespan, focusing on mechanisms of action, safety profiles, and clinical applications. Here we show that combined oralcontraceptives (COCs) are generally safe for bone mineral density (BMD) in adult women;however, caution is advised in adolescence, especially with very low-dose estrogen formulations.In hypogonadal women, postmenopausal hormone replacement therapy (HRT) is key forosteoporosis prevention. Physiological regimens, preferably transdermal estrogen at doseshigher than those used in typical postmenopausal therapy, may offer better bone protection.Additionally, oral gonadotropin-releasing hormone receptor (GnRH-R) antagonists combinedwith add-back therapy represent a novel long-term option for managing uterine fibroids andendometriosis without compromising BMD. In postmenopausal women, both HRT and selectiveestrogen receptor modulators (SERMs) effectively reduce fracture risk and support bone health. Main results & implications: Optimizing therapeutic strategies to balance efficacy and safety, iscritical to ensuring personalized care that preserves bone health and enhances quality of lifeacross a woman’s lifespan.
- 18 February 2026
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (10) , 1-16
Open AccessImpact of estroprogestin therapies on bone health from adolescence to postmenopause
Background: Estrogens are fundamental to bone health, exerting life-long effects onbone metabolism. They regulate skeletal growth and maturation during adolescence andmaintain bone remodeling in adulthood. The decline in estrogen levels during perimenopauseand postmenopause leads to bone mass loss. Emerging evidence also supports a role forprogestins in bone metabolism. Several estrogen-progestins formulations are available andwidely used for contraception in fertile women and as hormone replacement therapy (HRT) incases of primary or secondary ovarian insufficiency as well as in physiologic menopause.Advances in both synthetic and natural preparations allowed for more personalized treatmentapproaches. When selecting estrogen-progestin therapies, it is essential to consider their impacton bone health and remodelling. Objective: This narrative review examines the effects of variousestrogen-progestin regimens on bone metabolism across the female lifespan, focusing on mechanisms of action, safety profiles, and clinical applications. Here we show that combined oralcontraceptives (COCs) are generally safe for bone mineral density (BMD) in adult women;however, caution is advised in adolescence, especially with very low-dose estrogen formulations.In hypogonadal women, postmenopausal hormone replacement therapy (HRT) is key forosteoporosis prevention. Physiological regimens, preferably transdermal estrogen at doseshigher than those used in typical postmenopausal therapy, may offer better bone protection.Additionally, oral gonadotropin-releasing hormone receptor (GnRH-R) antagonists combinedwith add-back therapy represent a novel long-term option for managing uterine fibroids andendometriosis without compromising BMD. In postmenopausal women, both HRT and selectiveestrogen receptor modulators (SERMs) effectively reduce fracture risk and support bone health. Main results & implications: Optimizing therapeutic strategies to balance efficacy and safety, iscritical to ensuring personalized care that preserves bone health and enhances quality of lifeacross a woman’s lifespan.